Loading
A phase 3 trial of Durvalumab, Tremelimumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) is a phase 3 interventional study registered as NCT05883644 by AstraZeneca, with 111 participants enrolled, started 2023-06-27 and due to reach its primary completion in 2026-03-30. Interventions recorded: Durvalumab, Tremelimumab. Conditions listed: Advanced Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), Durvalumab, AstraZeneca.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Tremelimumab, Durvalumab, AstraZeneca, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Tremelimumab, Advanced hepatocellular carcinoma (BCLC C), AstraZeneca, Hepatocellular carcinoma.
Shares Durvalumab, AstraZeneca, Hepatocellular carcinoma, Immune checkpoint inhibitors.